Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview

Our plain-English summary of Emerging Strategies in the Diagnosis and Treatment of Pleural Mesothelioma: An Overview, by R. Pagliaro, B. Leonardi, A. Schiattarella, et al (Thoracic Cancer, 2026).

The study

• Authors: R. Pagliaro, B. Leonardi, A. Schiattarella, G. Bergameo, C. Picone, A.G. D'Errico, F. Scialò, F. Perrotta, M.L. De Rimini, A. Fiorelli, A. Bianco
• Journal: Thoracic Cancer
• Published: 2026;17(8):e70259
• Type of article: Review
• Read it: PubMed · Publisher · Free full text

Abstract

Pleural mesothelioma (PM) is a rare and aggressive cancer arising from pleural mesothelial cells with a strong association to asbestos exposure. Among the diagnostic strategies available are noninvasive techniques including thoracic ultrasound (TUS), computed tomography (CT) scans, positron emission tomography (PET-CT), and invasive procedures such as thoracoscopy and pleural biopsy. Accurate identification of the histological subtype is critical for tailoring treatment strategies. The standard treatment for unresectable PM has traditionally been chemotherapy, particularly platinum and pemetrexed. However, recent advances in translational clinical research, including immune checkpoint inhibitors (ICIs), are changing the therapeutic landscape, offering new opportunities for personalized treatment. The recent FDA approval of nivolumab and ipilimumab combination therapy as a first-line treatment has significantly improved outcomes, especially for nonepithelioid subtypes. Ongoing studies are exploring additional immune-targeted therapies such as VISTA, LAG-3, and dendritic cell-based therapies. Early detection, refined biomarker identification, and a deeper understanding of the tumor microenvironment remain essential to improving PM prognosis and patient survival. This review provides a comprehensive exploration of the epidemiology, etiology, clinical manifestations, diagnostic approaches (including immunohistochemical and molecular markers), staging, and current treatment strategies for PM.

© 2026 The Author(s). Thoracic Cancer published by John Wiley & Sons Australia, Ltd.

In plain English

This article was a narrative review rather than a new study. The authors summarized published research on pleural mesothelioma. It named asbestos as the main risk factor. A table stated that all fiber types are carcinogenic, with the amphiboles (crocidolite, amosite, tremolite, anthophyllite, actinolite) most potent. Drawing on other studies, it reported that the latency between exposure and disease is generally 10 to 50 years. Latency is shorter with heavier or prolonged occupational exposure and longer after lighter, indirect or domestic exposure, sometimes beyond 50 years. Median survival was reported as around 12 to 14 months. It also discussed ionizing radiation and genetic factors such as BAP1 mutations. The review reported that thoracoscopy has a diagnostic yield of over 95%, while pleural fluid cytology is often inconclusive. It described the CheckMate 743 trial of first-line treatment in 605 patients with unresectable pleural mesothelioma. In that trial, median overall survival was 18.1 months with nivolumab plus ipilimumab versus 14.1 months with platinum-based chemotherapy. The authors concluded that asbestos remains the primary risk factor and that this combination offers survival benefits, especially for nonepithelioid subtypes.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published literature on pleural mesothelioma (epidemiology, causes, clinical presentation, diagnosis, biomarkers, staging and treatment); no new data were collected
• Who was studied: No study population; the authors reviewed previously published studies, trials and guidelines on pleural mesothelioma
• Exposure: Asbestos was the main risk factor discussed. A table classified chrysotile (serpentine) as having moderate carcinogenic potential, and the amphiboles amosite, crocidolite, tremolite, anthophyllite and actinolite as having high or very high potential. The review also covered ionizing radiation, erionite, other mineral fibers and genetic susceptibility.
• Main results:
  • The review described a latency period between exposure and tumor development that is generally observed to range from 10 to 50 years
  • Citing other studies, the review reported that heavier or prolonged occupational exposure is associated with shorter latency. Lighter, indirect or domestic exposure was linked to longer latency, with median values over 40 years and upper limits beyond 50 years in some populations.
  • Citing other sources, the review reported that most patients are diagnosed at an advanced stage, with a median survival of around 12 to 14 months
  • The review reported that the diagnostic yield of thoracoscopy for pleural mesothelioma is over 95%
  • The review reported that pleural fluid cytology has a sensitivity between 30% and 75% for diagnosing pleural mesothelioma
  • As reported by the review, the CheckMate 743 trial compared first-line nivolumab plus ipilimumab with first-line platinum-based chemotherapy in 605 patients with unresectable pleural mesothelioma. Median overall survival was 18.1 months in the nivolumab plus ipilimumab group versus 14.1 months in the chemotherapy group.
  • In their conclusion, the authors stated that the approval of nivolumab and ipilimumab offers significant survival benefits, especially for nonepithelioid subtypes
• The authors' conclusion: The authors concluded that asbestos exposure remains the primary risk factor for pleural mesothelioma, acting through progressive inflammation, DNA damage and tumor formation

Topics

The National Library of Medicine indexes this study under subjects our site covers: Mesothelioma.

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Mesothelial Cells, Asbestos Exposure, Ultrasound, PET-CT, Thoracoscopy, Pleural Biopsy, Histological Subtype.

Related studies

• Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies — L. Chiec, D.S. Bruno (2024)
• MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches — S. Cedres, L. Masfarre, et al. (2026)
• Telomeres and telomerase in mesothelioma: Pathophysiology, biomarkers and emerging therapeutic strategies (Review) — D. Andreikos, D.A. Spandidos, et al. (2025)
• Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights — R. López-Castro, Á. Fuentes-Martín, et al. (2024)
• From biology to therapy: current standards and emerging strategies in pleural mesothelioma — J.H.L.T. van Genugten, C.J. de Gooijer, et al. (2026)
• Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study — S. Yaşar, F. Yılmaz, et al. (2024)

Browse more research in Thoracic Cancer, or return to medical research.